Roth Keeps Regeneron (REGN) at 'Buy' Following Q4 Numbers, Outlook; VISTA, OUTLOOK Still in Focus

February 12, 2014 1:26 PM

Roth Capital affirms its Buy rating and $362 price target on Regeneron Pharmaceuticals (Nasdaq: REGN) following Q4 results.

Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found